KDNY

Chinook Therapeutics, Inc. Common Stock
KDNY

Overview Fund Activity
Delisted

KDNY was delisted on the 10th of August, 2023.

Back to rankings

157 hedge funds and large institutions have $1.42B invested in Chinook Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
157
Holders Change
+2
Holders Change %
+1.29%
% of All Funds
2.51%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.1%
New
20
Increased
57
Reduced
49
Closed
16
Calls
$5.61M
Puts
$1M
Net Calls
+$4.61M
Net Calls Change
+$3.95M

Top Buyers

1
Franklin Resources
Franklin Resources
California
$30.4M
2
EAM
Eventide Asset Management
Massachusetts
$33.3M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
$39.4M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
$31.7M
5
Federated Hermes
Federated Hermes
Pennsylvania
$29M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
$33.7M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
$16.9M
3
Citadel Advisors
Citadel Advisors
Florida
$2.6M
4
EC
EcoR1 Capital
California
$10.3M
5
Millennium Management
Millennium Management
New York
$5.75M
Name Holding Trade Value Shares
Change 		Shares
Change %
DCM
26
Driehaus Capital Management
Illinois
$17.5M -$402K -17,364 -2%
Nuveen Asset Management
27
Nuveen Asset Management
Illinois
$17.3M -$3.95M -170,593 -19%
Point72 Asset Management
28
Point72 Asset Management
Connecticut
$16.9M -$12.4M -535,491 -42%
RCMNY
29
Rubric Capital Management (New York)
New York
$16.7M – – –
Northern Trust
30
Northern Trust
Illinois
$12.3M -$16.4K -708 -0.1%
RSCM
31
Rock Springs Capital Management
Maryland
$11.7M – – –
SVCM
32
Saturn V Capital Management
Texas
$11.7M +$1.94M +83,641 +20%
Baillie Gifford & Co
33
Baillie Gifford & Co
United Kingdom
$11.3M -$72.1K -3,113 -0.6%
EC
34
EcoR1 Capital
California
$10.3M -$5.66M -244,450 -35%
Walleye Capital
35
Walleye Capital
New York
$9.12M +$6.08M +262,725 +200%
Charles Schwab
36
Charles Schwab
California
$8.75M -$129K -5,585 -1%
Ensign Peak Advisors
37
Ensign Peak Advisors
Utah
$8.38M – – –
Goldman Sachs
38
Goldman Sachs
New York
$8.09M +$3.17M +137,130 +65%
IBT
39
International Biotechnology Trust
United Kingdom
$7.41M -$472K -20,400 -6%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$7.4M -$928K -40,079 -11%
Bank of America
41
Bank of America
North Carolina
$7.28M +$3.23M +139,652 +80%
EAM
42
Erste Asset Management
Austria
$7.12M – – –
ACM
43
Altium Capital Management
New York
$7.06M -$1.85M -80,000 -21%
IC
44
Ikarian Capital
Texas
$6.56M – – –
Fidelity Investments
45
Fidelity Investments
Massachusetts
$6.13M -$973K -42,050 -14%
AG
46
Artal Group
Luxembourg
$5.99M +$5.99M +258,687 New
Morgan Stanley
47
Morgan Stanley
New York
$5.83M -$698K -30,171 -11%
Millennium Management
48
Millennium Management
New York
$5.75M -$4.45M -192,284 -44%
Two Sigma Advisers
49
Two Sigma Advisers
New York
$4.97M -$512K -22,100 -9%
MB
50
MPM BioImpact
Massachusetts
$4.58M +$2.73M +117,806 +147%
1
2
3 4 5